A new immediately-in-effect guidance document from the US Food and Drug Administration explains how makers of COVID-19 diagnostics can assess whether their tests are as effective when faced with coronavirus variants.
The guidance for test developers is one of four documents released by the FDA on 22 February. The other guidances address vaccines and therapeutics for COVID-19.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?